Markets open

AstraZeneca PLC Ordinary Shares

AZN · NYSE

Sep 2026upcoming

Next quarter

Consensus is $2.64 EPS for Sep 2026 across 3 estimates, ranging $2.60 to $2.69.

AZN Jun 2026

Reported Jul 27, 2026

Beat 5.20%

EPS estimate: $2.50
EPS actual: $2.63
Revenue estimate: —
Revenue actual: —
1-day move: +1.67%

Call highlights have not been generated for this quarter.

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

A reported $400 billion combination with Bristol Myers Squibb could expand AstraZeneca’s pharmaceutical portfolio and strengthen its competitive position across major therapeutic areas.

Bearish view

The scale of the reported transaction could create substantial execution, financing, regulatory and integration risks, potentially destroying value even if the strategic rationale is sound.